Healthcare Industry News: Bristol-Myers Squibb
News Release - June 10, 2009
ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical OfficerSEATTLE--(HSMN NewsFeed)--ZymoGenetics, Inc. (NASDAQ: ZGEN ) announced today that Eleanor L. Ramos, M.D. has been named Senior Vice President and Chief Medical Officer and will serve as a member of the executive management committee. Dr. Ramos is replacing Dr. Nicole Onetto, the company’s former Chief Medical Officer.
“With 15 years of biopharma experience, Dr. Ramos brings a wealth of knowledge to her new role as Chief Medical Officer,” said Douglas E. Williams, Chief Executive Officer of ZymoGenetics. “Most recently, she oversaw the clinical strategy for our immunology pipeline and managed the clinical development functions that contributed to the success of the PEG-Interferon lambda clinical trial program. Dr. Ramos has demonstrated the ability to bring novel immunology therapeutics forward to help patients.”
Dr. Eleanor L. Ramos joined ZymoGenetics in January 2007 as Vice President, Clinical Research, Immunology and Inflammation and became Vice President, Clinical Development in 2008. Prior to joining ZymoGenetics, Dr. Ramos held senior positions at Bristol-Myers Squibb and the Immune Tolerance Network, the latter of which involved the management of a multidisciplinary group involved in the design and execution of clinical trials in autoimmunity, asthma, allergy and transplantation. She has also contributed to the development of CellCept and Zenapax in solid organ transplantation while at Roche Global Development, Palo Alto, CA. Dr. Ramos has also held a number of academic appointments at Harvard Medical School, University of Florida, Yale University and University of California, San Francisco. Before making the move to industry, Dr. Ramos, as a board-certified Internist with a sub-specialty in Nephrology, was Director of the Renal Transplant Services at the Brigham and Women’s Hospital, Boston and University of Florida, Gainesville. Dr. Ramos earned a B.S. summa cum laude in Chemistry from Tufts University and received her medical degree with Alpha Omega Alpha distinction from Tufts Medical School. She completed her residency in Internal Medicine at Tufts-New England Medical Center, Boston and fellowship in Nephrology/Transplant Immunology at the Brigham and Women’s Hospital, Harvard Medical School, Boston.
ZymoGenetics creates novel protein drugs that help patients fight disease. The company developed and markets RECOTHROM® Thrombin, topical (Recombinant). Other product candidates are focused on cancer, autoimmune and viral diseases. ZymoGenetics intends to commercialize product candidates through internal development, collaborations with partners, and out-licensing of patents from its extensive patent portfolio. For further information, visit www.zymogenetics.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future actions and involve risks and uncertainties that are difficult to predict. ZymoGenetics actual actions and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with management changes, our unproven discovery strategy, preclinical and clinical development, regulatory oversight, product sales and marketing abilities, strategic partnering, intellectual property claims and litigation, and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2008 and subsequent Quarterly Reports on Form 10-Q. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.